Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2020-02-06 Fund Information / Fact…
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Fund Information / Factsheet Classification · 90% confidence The document consists of a brief tabular listing of dates, fund/investor names, venues, and types of meetings, indicating a schedule or summary of investor meetings or conferences. There is no detailed financial data, no regulatory references, no report attachments, and the document is very short (484 characters). It does not contain any financial results, management discussion, or voting results. This type of content aligns best with a Fund Information / Factsheet (FS) category, which typically provides brief summaries of key company facts or market-related event schedules. Given the brevity and nature of the content, confidence is high.
2020-02-06 English
Please find enclosed letter dated 6th February 2020.
Regulatory Filings Classification · 90% confidence The document consists of a brief tabular listing of dates, fund/investor names, venues, and types of meetings, indicating a schedule or summary of investor meetings or conferences. There is no detailed financial data, no regulatory or legal content, no voting results, no management changes, and no report attachments or references. The document is very short (486 characters) and does not contain any substantive report or announcement content. It appears to be a simple investor meeting schedule or summary, which does not fit into any of the specific detailed categories such as Annual Report, Earnings Release, or Management Reports. Given the lack of fit and the nature of the content, the best classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not neatly fit into other categories.
2020-02-06 English
Please find enclosed letter dated 5th February, 2020.
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data including quarterly, nine months, and year ended figures for revenue, profit before tax, profit after tax, earnings per share, and equity share capital. The data is unaudited for interim periods and audited for the year ended. The presence of multiple quarterly and nine months periods with unaudited financials and a year-end audited figure indicates this is a comprehensive financial report for a period shorter than a full fiscal year. There is no indication that this is an announcement or a summary; the document contains substantive financial data and analysis. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). The document length is 2160 characters, which is consistent with a concise interim report rather than a brief announcement or certification.
2020-02-05 English
Updates
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data including quarterly and nine-month periods, with figures for revenue, profit before and after tax, earnings per share, and equity. The data is unaudited for interim periods and audited for the year ended 31-03-2019. The presence of multiple quarterly and nine-month periods with unaudited financials indicates this is a comprehensive interim or quarterly financial report rather than a brief earnings release or an annual report. The document length is 2160 characters, which is relatively short but contains substantive financial data, so it is not merely an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2020-02-05 English
Please find enclosed letter dated 5th February 2020.
Regulatory Filings
2020-02-05 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial statement including unaudited consolidated financial results for the quarter and nine months ended 31st December 2019. It includes comprehensive financial data such as revenue, expenses, profit before tax, tax expenses, net profit, segment information, and notes on accounting standards. The document references Regulation 30 and 33 of SEBI Listing Regulations and includes a limited review report by the statutory auditor. The presence of detailed financial statements and analysis for a period shorter than a full fiscal year (quarter and nine months) indicates this is an Interim / Quarterly Report. It is not merely an announcement or a certification, but contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR).
2020-02-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.